More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular Diseases - PubMed
7 days ago
- #glomerular disease
- #SGLT2 inhibitors
- #nephroprotection
- SGLT2 inhibitors show nephroprotective effects in diverse populations, including non-diabetic glomerular disease patients.
- Benefits extend beyond glucose elimination, affecting inflammation, immunity, autophagy, and metabolic pathways.
- Modulates inflammatory pathways relevant to IgA glomerulonephritis, lupus nephritis, and ANCA-associated vasculitis.
- Influences immune cell metabolism, T-cell activation, and potentially B-cell and macrophage polarization.
- Autophagy may have dual roles in glomerular disease, either triggering immunity or protecting podocytes.
- Reduces ferroptosis and modulates hypoxia responses, potentially attenuating kidney damage.
- Activates nutrient-sensing pathways (AMPK, sirtuins, mTOR) and upregulates ketogenesis for metabolic reprogramming.
- Increases kidney Klotho and liver betaine, preserving anti-aging, anti-inflammatory, and antifibrotic effects.
- Preclinical and emerging human data suggest therapeutic advantages beyond kidney-cardiovascular protection.